Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 09 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2023 Planned End Date changed from 1 Dec 2023 to 1 Sep 2024.
- 20 Jul 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.